HUP9800115A1 - Rifaximin alkalmazása kriptosporidiózis következtében fellépő hasmenés kezelésére használható gyógyszerkészítmények előállítására - Google Patents
Rifaximin alkalmazása kriptosporidiózis következtében fellépő hasmenés kezelésére használható gyógyszerkészítmények előállításáraInfo
- Publication number
- HUP9800115A1 HUP9800115A1 HU9800115A HUP9800115A HUP9800115A1 HU P9800115 A1 HUP9800115 A1 HU P9800115A1 HU 9800115 A HU9800115 A HU 9800115A HU P9800115 A HUP9800115 A HU P9800115A HU P9800115 A1 HUP9800115 A1 HU P9800115A1
- Authority
- HU
- Hungary
- Prior art keywords
- rifaximin
- cryptosporediosis
- preparation
- pharmaceutical compositions
- immune system
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title abstract 2
- 229960003040 rifaximin Drugs 0.000 title abstract 2
- 206010012735 Diarrhoea Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000008953 Cryptosporidiosis Diseases 0.000 abstract 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000000741 diarrhetic effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A találmány tárgya rifaximin alkalmazása kriptőspőridiózisős(Cryptőspőridiűm parvűm fertőzés) esetek hasmenéses tüneteinekkezelésére - imműndepresszió (az imműnrendszer csökkent működése)súlyős főrmáiban szenvedő betegeknél, példáűl AIDS-ben (szerzettimműnhiányős tünetegyüttesben), vagy rősszindűlatú daganatképződésbenszenvedő, vagy szervátültetésen átesett, vagy kemőterápiásan, illetveimműnszűppresszív (az imműnrendszer működését gátló) hatóanyagőkkalkezelt betegeknél - szőlgáló gyógyszerkészítmények előállítására. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT97BO000064A IT1290679B1 (it) | 1997-02-14 | 1997-02-14 | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
Publications (4)
Publication Number | Publication Date |
---|---|
HU9800115D0 HU9800115D0 (en) | 1998-03-30 |
HUP9800115A1 true HUP9800115A1 (hu) | 1999-06-28 |
HUP9800115A3 HUP9800115A3 (en) | 2000-04-28 |
HU224592B1 HU224592B1 (hu) | 2005-11-28 |
Family
ID=11341939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9800115A HU224592B1 (hu) | 1997-02-14 | 1998-01-22 | Rifaximin alkalmazása kriptosporidiózis következtében fellépő hasmenés kezelésére használható gyógyszerkészítmény előállítására |
Country Status (12)
Country | Link |
---|---|
US (1) | US5886002A (hu) |
EP (1) | EP0858804B1 (hu) |
JP (1) | JP4848083B2 (hu) |
KR (1) | KR100436243B1 (hu) |
CN (1) | CN1115146C (hu) |
AT (1) | ATE218342T1 (hu) |
DE (1) | DE69805672T2 (hu) |
DK (1) | DK0858804T3 (hu) |
ES (1) | ES2178048T3 (hu) |
HU (1) | HU224592B1 (hu) |
IT (1) | IT1290679B1 (hu) |
PT (1) | PT858804E (hu) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
AU2004236173B2 (en) * | 2003-04-30 | 2008-07-03 | The Institutes For Pharmaceutical Discovery, Llc | Substituted carboxylic acids |
US20060210483A1 (en) * | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections |
US8003118B2 (en) * | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
US20060210492A1 (en) * | 2005-03-02 | 2006-09-21 | Kodsi Robert E | Use of rifaximin for treatment and prevention of periodontal conditions |
PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
DK2054066T3 (en) * | 2006-08-02 | 2015-06-08 | Salix Pharmaceuticals Inc | METHODS OF TREATMENT OF RADIATE ENTERITIS |
US20080161337A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Chronic Prostatitis |
US20080159987A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Restless Legs Syndrome |
CA2736285C (en) | 2008-09-26 | 2016-08-23 | Aska Pharmaceutical Co., Ltd. | Agent for preventing and/or treating functional gastrointestinal disorder |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
WO2010040020A1 (en) | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
NZ600362A (en) | 2009-11-23 | 2014-08-29 | Cipla Ltd | Topical foam composition |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
JP6092629B2 (ja) * | 2010-03-10 | 2017-03-08 | ルピン・リミテッドLupin Limited | リファキシミン使用準備済懸濁液 |
KR20140029356A (ko) | 2010-09-13 | 2014-03-10 | 시플라 리미티드 | 약학 조성물 |
WO2012076832A1 (en) | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
NZ723571A (en) | 2014-05-12 | 2020-02-28 | Alfasigma Spa | New solvated crystal form of rifaximin, production, compositions and uses thereof |
WO2016003536A1 (en) * | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
WO2016138118A1 (en) * | 2015-02-26 | 2016-09-01 | Jaguar Animal Health, Inc. | Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals |
JP6817966B2 (ja) * | 2015-06-10 | 2021-01-20 | シンロジック オペレーティング カンパニー インコーポレイテッド | 高アンモニア血症に関連する疾患を治療するために操作された細菌 |
AU2017343886B2 (en) | 2016-10-14 | 2023-07-06 | Cipla Limited | Pharmaceutical compositions comprising rifaximin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1264494B1 (it) * | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter |
-
1997
- 1997-02-14 IT IT97BO000064A patent/IT1290679B1/it active IP Right Grant
-
1998
- 1998-01-22 DK DK98101081T patent/DK0858804T3/da active
- 1998-01-22 DE DE69805672T patent/DE69805672T2/de not_active Expired - Lifetime
- 1998-01-22 ES ES98101081T patent/ES2178048T3/es not_active Expired - Lifetime
- 1998-01-22 HU HU9800115A patent/HU224592B1/hu active IP Right Grant
- 1998-01-22 PT PT98101081T patent/PT858804E/pt unknown
- 1998-01-22 AT AT98101081T patent/ATE218342T1/de active
- 1998-01-22 EP EP98101081A patent/EP0858804B1/en not_active Expired - Lifetime
- 1998-01-26 US US09/013,655 patent/US5886002A/en not_active Expired - Lifetime
- 1998-02-12 JP JP02981398A patent/JP4848083B2/ja not_active Expired - Lifetime
- 1998-02-13 KR KR10-1998-0004389A patent/KR100436243B1/ko not_active IP Right Cessation
- 1998-02-13 CN CN98106920A patent/CN1115146C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ITBO970064A1 (it) | 1998-08-14 |
EP0858804A1 (en) | 1998-08-19 |
HU224592B1 (hu) | 2005-11-28 |
HUP9800115A3 (en) | 2000-04-28 |
KR100436243B1 (ko) | 2004-08-25 |
DE69805672T2 (de) | 2003-01-23 |
ATE218342T1 (de) | 2002-06-15 |
JPH10226645A (ja) | 1998-08-25 |
KR19980071348A (ko) | 1998-10-26 |
IT1290679B1 (it) | 1998-12-10 |
US5886002A (en) | 1999-03-23 |
PT858804E (pt) | 2002-10-31 |
ITBO970064A0 (it) | 1997-02-14 |
CN1214244A (zh) | 1999-04-21 |
ES2178048T3 (es) | 2002-12-16 |
DK0858804T3 (da) | 2002-07-08 |
CN1115146C (zh) | 2003-07-23 |
JP4848083B2 (ja) | 2011-12-28 |
HU9800115D0 (en) | 1998-03-30 |
EP0858804B1 (en) | 2002-06-05 |
DE69805672D1 (de) | 2002-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9800115A1 (hu) | Rifaximin alkalmazása kriptosporidiózis következtében fellépő hasmenés kezelésére használható gyógyszerkészítmények előállítására | |
IL149995A0 (en) | Depsipeptides and pharmaceutical compositions containing the same | |
NO20092874L (no) | Forhindring og behandling av amyloidogen sykdom | |
NO20100777L (no) | Kinazolinoner, slike forbindelser for anvendelse som medikament, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom | |
FR2757520B1 (fr) | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent | |
ATE297208T1 (de) | Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit | |
FR2757522B1 (fr) | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
DE69426334T2 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
ATE392902T1 (de) | Nigella sativa als medizinische behandlung | |
PT1429845E (pt) | Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
AU1794601A (en) | Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs | |
HUP0003904A1 (hu) | Ciklosporinok és tacrolimus által okozott nephrotoxicitas megelőzésére alkalmas eljárás | |
IL121272A (en) | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia | |
MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
BG93298A (bg) | Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни | |
TR200401810T4 (tr) | Kısırlık tedavisinde fsh'ın kullanılması | |
HUP0003256A2 (hu) | Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
HK1045456A1 (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
DE69819922D1 (de) | 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten | |
GB2407321A (en) | Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor | |
HUP9901299A2 (hu) | Attenuált, nemimmunogén poxvírusokból vagy parapoxvírusokból előállított multipotens parapox immunitást előidéző gyógyszerek használatának új indikációi | |
Arnaud et al. | Interim analysis of a double-blind phase-III clinical trial of adjuvant levamisole versus control in resectable Dukes-C colon cancer: A study of the EORTC Gastrointestinal Tract Cancer Cooperative Group | |
Fowler | AIDS survival progress | |
Smart | Protease inhibitors come of age |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HFG4 | Patent granted, date of granting |
Effective date: 20051003 |